Cite
Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer
MLA
Emmanuel S. Antonarakis, and Benjamin L. Maughan. “Olaparib and Rucaparib for the Treatment of DNA Repair-Deficient Metastatic Castration-Resistant Prostate Cancer.” Expert Opinion on Pharmacotherapy, vol. 22, Apr. 2021, pp. 1625–32. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f673705fb661ebc9c62549756e27e145&authtype=sso&custid=ns315887.
APA
Emmanuel S. Antonarakis, & Benjamin L. Maughan. (2021). Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer. Expert Opinion on Pharmacotherapy, 22, 1625–1632.
Chicago
Emmanuel S. Antonarakis, and Benjamin L. Maughan. 2021. “Olaparib and Rucaparib for the Treatment of DNA Repair-Deficient Metastatic Castration-Resistant Prostate Cancer.” Expert Opinion on Pharmacotherapy 22 (April): 1625–32. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f673705fb661ebc9c62549756e27e145&authtype=sso&custid=ns315887.